260 related articles for article (PubMed ID: 28279415)
1. Proteasome Inhibitors as a Potential Cause of Heart Failure.
Koulaouzidis G; Lyon AR
Heart Fail Clin; 2017 Apr; 13(2):289-295. PubMed ID: 28279415
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology differences among proteasome inhibitors: Implications for their use in clinical practice.
Fogli S; Galimberti S; Gori V; Del Re M; Danesi R
Pharmacol Res; 2021 May; 167():105537. PubMed ID: 33684510
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibitors for the treatment of multiple myeloma.
Scalzulli E; Grammatico S; Vozella F; Petrucci MT
Expert Opin Pharmacother; 2018 Mar; 19(4):375-386. PubMed ID: 29478351
[TBL] [Abstract][Full Text] [Related]
4. Three new drugs for multiple myeloma.
Med Lett Drugs Ther; 2016 May; 58(1495):e70-1. PubMed ID: 27192621
[No Abstract] [Full Text] [Related]
5. Management of Gastrointestinal Toxicities From Ixazomib: Tips to Curb Nausea, Vomiting, Diarrhea, and Constipation.
Hall KH
Oncology (Williston Park); 2019 Mar; 33(3):89-90. PubMed ID: 30866030
[No Abstract] [Full Text] [Related]
6. Proteasome inhibitors: structure and function.
Nunes AT; Annunziata CM
Semin Oncol; 2017 Dec; 44(6):377-380. PubMed ID: 29935898
[TBL] [Abstract][Full Text] [Related]
7. Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma.
Salvini M; Bonello F; Boccadoro M; Larocca A
Expert Rev Anticancer Ther; 2017 Jan; 17(1):75-87. PubMed ID: 27894203
[TBL] [Abstract][Full Text] [Related]
8. Ixazomib for the treatment of multiple myeloma.
Gentile M; Offidani M; Vigna E; Corvatta L; Recchia AG; Morabito L; Morabito F; Gentili S
Expert Opin Investig Drugs; 2015; 24(9):1287-98. PubMed ID: 26138345
[TBL] [Abstract][Full Text] [Related]
9. [Role of novel proteasome inhibitors in the treatment of relapsed/refractory multiple myeloma].
Ri M
Rinsho Ketsueki; 2018; 59(10):2162-2168. PubMed ID: 30305522
[TBL] [Abstract][Full Text] [Related]
10. Safety of proteasome inhibitors for treatment of multiple myeloma.
Schlafer D; Shah KS; Panjic EH; Lonial S
Expert Opin Drug Saf; 2017 Feb; 16(2):167-183. PubMed ID: 27841029
[TBL] [Abstract][Full Text] [Related]
11. A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.
Laubach JP; Moslehi JJ; Francis SA; San Miguel JF; Sonneveld P; Orlowski RZ; Moreau P; Rosiñol L; Faber EA; Voorhees P; Mateos MV; Marquez L; Feng H; Desai A; van de Velde H; Elliott J; Shi H; Dow E; Jobanputra N; Esseltine DL; Niculescu L; Anderson KC; Lonial S; Richardson PG
Br J Haematol; 2017 Aug; 178(4):547-560. PubMed ID: 28466536
[TBL] [Abstract][Full Text] [Related]
12. Next-generation proteasome inhibitors for cancer therapy.
Park JE; Miller Z; Jun Y; Lee W; Kim KB
Transl Res; 2018 Aug; 198():1-16. PubMed ID: 29654740
[TBL] [Abstract][Full Text] [Related]
13. [Molecular targeting agents for multiple myeloma].
Fujii S; Abe M
Nihon Rinsho; 2012 Nov; 70 Suppl 8():518-23. PubMed ID: 23513894
[No Abstract] [Full Text] [Related]
14. Multiple myeloma--translation of trial results into reality.
Moreau P; Rajkumar SV
Lancet; 2016 Jul; 388(10040):111-3. PubMed ID: 27411865
[No Abstract] [Full Text] [Related]
15. Next-generation proteasome blockers promise safer cancer therapy.
Mullard A
Nat Med; 2012 Jan; 18(1):7. PubMed ID: 22227650
[No Abstract] [Full Text] [Related]
16. Spotlight on ixazomib: potential in the treatment of multiple myeloma.
Muz B; Ghazarian RN; Ou M; Luderer MJ; Kusdono HD; Azab AK
Drug Des Devel Ther; 2016; 10():217-26. PubMed ID: 26811670
[TBL] [Abstract][Full Text] [Related]
17. Ixazomib: First Global Approval.
Shirley M
Drugs; 2016 Mar; 76(3):405-11. PubMed ID: 26846321
[TBL] [Abstract][Full Text] [Related]
18. The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.
Richardson PG; Moreau P; Laubach JP; Gupta N; Hui AM; Anderson KC; San Miguel JF; Kumar S
Future Oncol; 2015; 11(8):1153-68. PubMed ID: 25832873
[TBL] [Abstract][Full Text] [Related]
19. Ixazomib in the management of relapsed multiple myeloma.
Touzeau C; Moreau P
Future Oncol; 2018 Aug; 14(20):2013-2020. PubMed ID: 29469592
[TBL] [Abstract][Full Text] [Related]
20. Oral ixazomib maintenance therapy in multiple myeloma.
Offidani M; Corvatta L; Gentili S; Maracci L; Leoni P
Expert Rev Anticancer Ther; 2016; 16(1):21-32. PubMed ID: 26588946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
